What exactly changed in the March 13, 2026 ACIU analyst rating?

Jefferies maintained a **Buy** on AC Immune S.A. on March 13, 2026. The note labeled 2025 financials as largely immaterial and provided no new price target.

Does the March 13 note include a new ACIU price target?

No. Jefferies did not publish a new ACIU price target in the March 13, 2026 note, leaving valuation to peers and pipeline milestones for now. Check the linked report for details.

How should investors interpret a maintained ACIU analyst rating?

A maintained ACIU analyst rating signals continued analyst conviction but not fresh positive catalysts. Investors should weigh the rating against clinical progress, cash runway, and overall risk appetite.

What is Meyka AI’s view after the ACIU analyst rating change?

Meyka AI rates ACIU with a grade of **B**, reflecting benchmark comparison, sector performance, financial growth, and analyst consensus. This is informational, not investment advice.

Analyst Ratings

Jefferies Maintains Buy on ACIU (AC Immune S.A.) March 2026

ByHuzaifa Zahoor March 16, 2026March 16, 2026

Jefferies on March 13, 2026 maintained a Buy on AC Immune S.A. (ACIU), the main ACIU analyst rating update this week. The firm said “2025 financials largely immaterial,” signaling focus on longer term catalysts. StreetInsider reported the note and the stock moved roughly -0.66% (-$-0.02) on the news. This ACIU analyst rating keeps Jefferies aligned with a positive view while not supplying a price target, leaving valuation questions for investors.